NDV-01 (sustained-release gemcitabine-docetaxel)

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder CancerNCT07464145RLMDPhase 3Not yet recruiting2029-12Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.